Nostetta Ventures

Sourcing relies on deep ties to universities and research centers in Finland’s North Savo region and beyond. Portfolio companies such as Marginum and Cleamix were initiated through collaborations with academic institutions, clinical partners, and national research bodies like VTT, giving Nostetta early access to commercialization-stage science.

The firm’s disclosed activity shows exclusively direct, equity-based investments into early-stage operating companies. There is no public record of Nostetta participating as a limited partner in external venture or private-equity funds.

Nostetta describes its strategy as early-stage, including start-up and growth phases. Portfolio entry points range from pre-revenue university spinouts, like Marginum in 2021, to expanding commercial-stage companies, like Kiho, which was scaling internationally when backed the same year.